These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37126928)

  • 1. Immunotherapy of Epstein-Barr virus (EBV) infection and EBV-associated hematological diseases with gp350/CD89-targeted bispecific antibody.
    He H; Lei F; Huang L; Wang K; Yang Y; Chen L; Peng Y; Liang Y; Tan H; Wu X; Feng M
    Biomed Pharmacother; 2023 Jul; 163():114797. PubMed ID: 37126928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sintilimab treatment for chronic active Epstein-Barr virus infection and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children.
    Chen R; Lin Q; Zhu Y; Shen Y; Xu Q; Tang H; Cui N; Jiang L; Dai X; Chen W; Li X
    Orphanet J Rare Dis; 2023 Sep; 18(1):297. PubMed ID: 37736751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
    Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
    Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
    Front Immunol; 2018; 9():932. PubMed ID: 29765376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Epstein-Barr Virus-Positive T/NK Lymphoproliferative Diseases With
    Ishimura M; Eguchi K; Shiraishi A; Sonoda M; Azuma Y; Yamamoto H; Imadome KI; Ohga S
    Front Pediatr; 2019; 7():183. PubMed ID: 31231620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum of Epstein-Barr virus-associated T-cell lymphoproliferative disorder in adolescents and young adults in Taiwan.
    Wang RC; Chang ST; Hsieh YC; Huang WT; Hsu JD; Tseng CE; Wang MC; Hwang WS; Wang J; Chuang SS
    Int J Clin Exp Pathol; 2014; 7(5):2430-7. PubMed ID: 24966953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the Epstein-Barr Virus gp350 IgA Antibody Response Are Associated With Increased Risk for Coinfection With a Second Strain of Epstein-Barr Virus.
    Smith NA; Baresel PC; Jackson CL; Ogolla S; Toko EN; Heit S; Piriou E; Sumba OP; Middeldorp JM; Colborn KL; Rochford R
    J Infect Dis; 2019 Feb; 219(6):955-963. PubMed ID: 30312417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late-onset posttransplant Epstein-Barr virusrelated lymphoproliferative disease after cord blood transplantation for chronic active Epstein Barr virus infection: A case report.
    Yamamoto M; Shindo M; Funayama T; Sumi C; Saito T; Toki Y; Hatayama M; Imadome KI; Mizukami Y; Okumura T
    Medicine (Baltimore); 2022 Mar; 101(12):e29055. PubMed ID: 35357349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes.
    El-Mallawany NK; Curry CV; Allen CE
    Br J Haematol; 2022 Jan; 196(1):31-44. PubMed ID: 34169507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.
    Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C
    J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr Virus gp350 Can Functionally Replace the Rhesus Lymphocryptovirus Major Membrane Glycoprotein and Does Not Restrict Infection of Rhesus Macaques.
    Herrman M; Mühe J; Quink C; Wang F
    J Virol; 2016 Feb; 90(3):1222-30. PubMed ID: 26559839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The superiority of Epstein-Barr virus DNA in plasma over in peripheral blood mononuclear cells for monitoring EBV-positive NK-cell lymphoproliferative diseases.
    Zheng M; Bao Y; Wang J; Ma Y; Yang Y; Zhang P; Chen L; Zheng K; Zhou J
    Hematol Oncol; 2022 Aug; 40(3):381-389. PubMed ID: 35405763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
    Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
    Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus (EBV) hyperimmune globulin isolated from donors with high gp350 antibody titers protect humanized mice from challenge with EBV.
    Kim J; Bu W; Mine S; Tariq Z; Nguyen H; Wang Y; Tolman C; Mond J; Cohen JI
    Virology; 2021 Sep; 561():80-86. PubMed ID: 34171765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection.
    Kasahara Y; Yachie A; Takei K; Kanegane C; Okada K; Ohta K; Seki H; Igarashi N; Maruhashi K; Katayama K; Katoh E; Terao G; Sakiyama Y; Koizumi S
    Blood; 2001 Sep; 98(6):1882-8. PubMed ID: 11535525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus central nervous system involvement in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
    Yin Q; Wang J; Wang Z
    Ann Hematol; 2022 Nov; 101(11):2471-2476. PubMed ID: 36071294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The understanding of Epstein-Barr virus associated lymphoproliferative disorder].
    Zhou XG; Zhang YL; Xie JL; Huang YH; Zheng YY; Li WS; Chen H; Liu F; Pan HX; Wei P; Wang Z; Hu YC; Yang KY; Xiao HL; Wu MJ; Yin WH; Mei KY; Chen G; Yan XC; Meng G; Xu G; Li J; Tian SF; Zhu J; Song YQ; Zhang WJ
    Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):817-821. PubMed ID: 28056294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
    Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
    Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
    [No Abstract]   [Full Text] [Related]  

  • 19. A clinicopathologic study of the spectrum of systemic forms of EBV-associated T-cell lymphoproliferative disorders of childhood: A single tertiary care pediatric institution experience in North America.
    Coffey AM; Lewis A; Marcogliese AN; Elghetany MT; Punia JN; Chang CC; Allen CE; McClain KL; Gaikwad AS; El-Mallawany NK; Curry CV
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27798. PubMed ID: 31099136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ambiguous boundary between EBV-related hemophagocytic lymphohistiocytosis and systemic EBV-driven T cell lymphoproliferative disorder.
    Smith MC; Cohen DN; Greig B; Yenamandra A; Vnencak-Jones C; Thompson MA; Kim AS
    Int J Clin Exp Pathol; 2014; 7(9):5738-49. PubMed ID: 25337215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.